Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882258 · ClinicalTrials.gov registry record · Phase 2
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00882258 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 144 participants.
The verdict
NCT00882258, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
Interventions
- DRUG Placebo
- DRUG 25 mg Proellex
- DRUG 12.5 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882258
The ClinicalTrials.gov registry entry for NCT00882258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00882258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882258 about?
NCT00882258 is a clinical study titled "Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids". Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
What is the current status of trial NCT00882258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2006-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00882258?
The interventions under investigation include: Placebo (DRUG), 25 mg Proellex (DRUG), 12.5 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT00882258?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.